Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 13/20 | 0.64 |
| ▸ | NAMPT | P43490 | 6/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249722 | 0.79 | ROCK2 (1.00) | ROCK2NAMPT | |
| SCHEMBL3245013 | 0.78 | ROCK2 (0.80) | ROCK2NAMPT | |
| SCHEMBL3249295 | 0.77 | ROCK2 (0.78) | ROCK2NAMPT | |
| SCHEMBL3239823 | 0.76 | NAMPT (0.69) | ROCK2NAMPT | |
| SCHEMBL3245134 | 0.75 | ROCK2 (0.79) | ROCK2NAMPT | |
| SCHEMBL8321101 | 0.75 | GSK3B (0.56) | ROCK2 | |
| SCHEMBL1394203 | 0.74 | RAB9A (0.74) | NAMPT | |
| SCHEMBL3249547 | 0.73 | ROCK2 (1.00) | ROCK2NAMPT | |
| SCHEMBL13391170 | 0.72 | ROCK2 (0.78) | ROCK2 | |
| SCHEMBL18317283 | 0.72 | CNR1 (0.76) | ROCK2NAMPTCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010036316-A1 | UREA AND CARBAMATE COMPOUNDS AND ANALOGS AS KINASE INHIBITORS | FENG YANGBO (US) | 2010-04-01 | — | — | WO | claimed |
| US-20210047278-A1 | E3 UBIQUITIN LIGASE AGONISTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE E3 UBIQUITIN LIGASE AGONISTS, RELATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-18 | — | — | US | disclosed |
| WO-2010036316-A1 | UREA AND CARBAMATE COMPOUNDS AND ANALOGS AS KINASE INHIBITORS | FENG YANGBO (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047278-A1 | E3 UBIQUITIN LIGASE AGONISTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE E3 UBIQUITIN LIGASE AGONISTS, RELATED METHODS OF USE | UBE3A, NEDD4, ADRM1 | ROCK2 4481/4885NAMPT 4522/4885CNR1 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.